Table 1.
Clinical data of 38 patients with Wilson’s disease with neurological deterioration during DPA treatment.
| Group 1 | Group 2 | |
|---|---|---|
| Patients (n) | 21 | 17 |
| Age at onset (range, median) | 18.9 ± 9.8 | 20.5 ± 11.2 |
| Mean duration of illness (months) | 18.6 ± 35.2 | 26.2 ± 43.8 |
| CP (mg/dl) | 7.0 ± 2.0 | 7.0 ± 3.0 |
| Kayser–Fleischer ring (n) | 19 | 14 |
| With neurologic symptoms (n) | 21 | 17 |
| With psychiatric symptoms (n) | 4 | 3 |
| With liver disease (n) | 18 | 15 |
| With splenomegaly (n) | 15 | 11 |
| Abnormal brain MRI (n) | 21 | 17 |
| Duration of DPA treatment (months) | 3.9 ± 2.7 | 3.7 ± 3.4 |
| Dose of DPA (mg/day) | 125~750 | 125~750 |
CP, ceruloplasmin; DPA, D-penicillamine; MRI, magnetic resonance imaging.